Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elezanumab in progressive multiple sclerosis
NCT03737812Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2019
- Primary completion
- Jan 2021
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of elezanumab in multiple sclerosis (MS), sponsored by AbbVie Inc.. Started Feb 2019; status: completed.
02
Drugs
elezanumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03737812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03737812.